Logo image of BCDA

BIOCARDIA INC (BCDA) Stock Fundamental Analysis

NASDAQ:BCDA - Nasdaq - US09060U6064 - Common Stock - Currency: USD

1.97  +0.16 (+8.54%)

Fundamental Rating

2

Taking everything into account, BCDA scores 2 out of 10 in our fundamental rating. BCDA was compared to 567 industry peers in the Biotechnology industry. BCDA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCDA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCDA has reported negative net income.
In the past year BCDA has reported a negative cash flow from operations.
In the past 5 years BCDA always reported negative net income.
BCDA had a negative operating cash flow in each of the past 5 years.
BCDA Yearly Net Income VS EBIT VS OCF VS FCFBCDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -213.37%, BCDA is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
The Return On Equity of BCDA (-949.34%) is worse than 82.89% of its industry peers.
Industry RankSector Rank
ROA -213.37%
ROE -949.34%
ROIC N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCDA Yearly ROA, ROE, ROICBCDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCDA Yearly Profit, Operating, Gross MarginsBCDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCDA has been increased compared to 1 year ago.
Compared to 5 years ago, BCDA has less shares outstanding
There is no outstanding debt for BCDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCDA Yearly Shares OutstandingBCDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BCDA Yearly Total Debt VS Total AssetsBCDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -65.26, we must say that BCDA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BCDA (-65.26) is worse than 95.06% of its industry peers.
There is no outstanding debt for BCDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -65.26
ROIC/WACCN/A
WACC10.2%
BCDA Yearly LT Debt VS Equity VS FCFBCDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

BCDA has a Current Ratio of 1.13. This is a normal value and indicates that BCDA is financially healthy and should not expect problems in meeting its short term obligations.
BCDA has a worse Current ratio (1.13) than 86.95% of its industry peers.
BCDA has a Quick Ratio of 1.13. This is a normal value and indicates that BCDA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BCDA (1.13) is worse than 85.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
BCDA Yearly Current Assets VS Current LiabilitesBCDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

BCDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.91%, which is quite good.
Looking at the last year, BCDA shows a very negative growth in Revenue. The Revenue has decreased by -87.74% in the last year.
Measured over the past years, BCDA shows a decrease in Revenue. The Revenue has been decreasing by -5.41% on average per year.
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.48%
Revenue 1Y (TTM)-87.74%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, BCDA will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
The Revenue is expected to grow by 70.56% on average over the next years. This is a very strong growth
EPS Next Y61.55%
EPS Next 2Y36.48%
EPS Next 3Y23.03%
EPS Next 5Y13.37%
Revenue Next Year-84.28%
Revenue Next 2Y-70.69%
Revenue Next 3Y-55.88%
Revenue Next 5Y70.56%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCDA Yearly Revenue VS EstimatesBCDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M 8M
BCDA Yearly EPS VS EstimatesBCDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BCDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCDA Price Earnings VS Forward Price EarningsBCDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCDA Per share dataBCDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

BCDA's earnings are expected to grow with 23.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.48%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCARDIA INC

NASDAQ:BCDA (4/25/2025, 8:00:01 PM)

1.97

+0.16 (+8.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)05-07 2025-05-07
Inst Owners2.72%
Inst Owner Change-73.43%
Ins Owners17.32%
Ins Owner Change1.69%
Market Cap9.22M
Analysts82.5
Price Target15.81 (702.54%)
Short Float %1.46%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)55.26%
Min EPS beat(2)49.74%
Max EPS beat(2)60.78%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)15.27%
EPS NY rev (3m)9.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 158.96
P/FCF N/A
P/OCF N/A
P/B 11.02
P/tB 11.02
EV/EBITDA N/A
EPS(TTM)-8.25
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0.01
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -213.37%
ROE -949.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.96%
Cap/Sales 10.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z -65.26
F-Score3
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)36.91%
Cap/Depr(5y)70.72%
Cap/Sales(3y)6.02%
Cap/Sales(5y)9.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.48%
EPS Next Y61.55%
EPS Next 2Y36.48%
EPS Next 3Y23.03%
EPS Next 5Y13.37%
Revenue 1Y (TTM)-87.74%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%-100%
Revenue Next Year-84.28%
Revenue Next 2Y-70.69%
Revenue Next 3Y-55.88%
Revenue Next 5Y70.56%
EBIT growth 1Y31.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.24%
EBIT Next 3Y-23.35%
EBIT Next 5Y-13.43%
FCF growth 1Y19.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.53%
OCF growth 3YN/A
OCF growth 5YN/A